Navigation Links
Genzyme Launches Cholestagel(R) in Europe
Date:10/23/2007

used on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements about the timing and geographies of Cholestagel's launch, as well as statements concerning Genzyme's plans to seek regulatory approval for Cholestagel in additional geographies. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the size of the market for the therapy in any particular geography, the sufficiency of reimbursement for the therapy in any particular geography; actions by governmental authorities related to Cholestagel, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) and Cholestagel(R) are registered trademarks of Genzyme Corporation and WelChol(R) is a registered trademark of Daiichi Sankyo Inc. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Co
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. Genzyme sues former Bone Care employees
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. Merge launches diagnostic mammography workstation in Europe
5. Einstein Wireless launches cellular alert system
6. Logistics Health launches compliance management tool
7. UW-Madison launches new high-speed research network
8. UWM launches research foundation
9. TeraMedica launches information manager
10. GE Healthcare launches hybrid electronic record
11. Cedara launches new version of DICOM toolkit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... which brings Q3 orders to $5.8 million and provides a good ... in North America and one in the ... bid new projects at record levels," said Peter Bruijns , ... at the end of Q3 than they have been for any ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report defines and ... and forecast of revenue. This market is estimated to ... by 2019, at a Compound Annual Growth Rate (CAGR) ... the TOC of the Asia-Pacific Speech Analytics market report ... It also provides a glimpse of the segmentation in ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... Today, competitors can copy the newest product enhancement, ... back-office process seemingly overnight. Indeed, it seems that ... This realization has led many corporate leaders to ... pursue is to create organizations that can respond ...
... an agreement Thursday with Capital Data, Inc. ... and financial services, according to TeraMEDICA's executive vice ... Data will bundle TeraMEDICA's TI2m archive solution into ... a territory that includes Wisconsin, Minnesota, North Dakota, ...
... , a unit of General Electric Company , ... ultrasound that is expected to increase efficiency for physicians. ... to perform the duties of larger-scale systems but in ... less. The system makes it possible for patients to ...
Cached Biology Technology:Going beyond me, too customer experiences 2Going beyond me, too customer experiences 3Going beyond me, too customer experiences 4TeraMEDICA and Capital Data enter into diagnostic imaging agreement 2GE Healthcare announces new, high-tech 'stethoscope' 2
(Date:10/17/2014)... knowledge regarding Ebola is critical and pertinent for practicing ... global outbreak and epidemic. The Journal, Disaster Medicine ... issue, Ebola Virus and Public Health, to surround the ... this critical societal moment. , On October 17, ... Clinicians . The primer was prepared by Dr. Eric ...
(Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2
... Switzerland June 7, 2008 The Cancer and ... phase II clinical trial showing that 70 percent of ... with galiximab, an investigational anti-CD80 monoclonal antibody, when given ... the study, 44 percent achieved a complete response and ...
... who dig dinosaurs in Eastern Montana will now be ... excavated and before degrading begins. Paleontologists from Montana ... Carolina Museum of Natural Sciences recently bought and renovated ... to Eastern Montana for the summer. The lab ...
... Media Fellows, Wendy Hansen and Maddalena Jackson, are ... part of a 10-week internship from June to August ... Wendy Hansen is a biophysics Ph.D. candidate ... 2008 graduate of Harvey,Mudd College, Claremont, Calif., with a ...
Cached Biology News:Galiximab in combination with rituximab in patients with previously untreated follicular lymphoma 2Dinosaur diggers bring mobile lab, new techniques to Eastern Montana 2Dinosaur diggers bring mobile lab, new techniques to Eastern Montana 3
MHC II (HLA-DP)...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
Biology Products: